Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Enterprise Value (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Enterprise Value data on record, last reported at -$184.2 million in Q4 2025.

  • For Q4 2025, Enterprise Value fell 94.27% year-over-year to -$184.2 million; the TTM value through Dec 2025 reached -$184.2 million, down 94.27%, while the annual FY2025 figure was -$184.2 million, 94.27% down from the prior year.
  • Enterprise Value reached -$184.2 million in Q4 2025 per TARS's latest filing, up from -$401.8 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$94.8 million in Q4 2024 and bottomed at -$407.9 million in Q1 2025.
  • Average Enterprise Value over 5 years is -$240.8 million, with a median of -$221.8 million recorded in 2022.
  • Peak YoY movement for Enterprise Value: tumbled 232.55% in 2021, then soared 58.31% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$171.8 million in 2021, then fell by 26.31% to -$217.0 million in 2022, then decreased by 4.8% to -$227.4 million in 2023, then skyrocketed by 58.31% to -$94.8 million in 2024, then tumbled by 94.27% to -$184.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$184.2 million in Q4 2025, -$401.8 million in Q3 2025, and -$381.1 million in Q2 2025.